EGFR and non-small cell lung carcinoma: Similarly, the BOOSTER study (A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations), a randomized phase 2 trial, failed to exhibit the efficacy of combination therapy, as no difference in median PFS was seen between combined osimertinib and bevacizumab therapy (15.4 mo; 95% CI: 9.2–18.0 mo) and osimertinib monotherapy (12.3 mo; 95% CI: 6.2–17.2 mo) (HR = 0.96, 95% CI: 0.68–1.37).35